Transgene – L'immunothérapie contre les cancers

Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors

S. Champiat, et al. ESMO 2024 Abstract available on the ESMO website – Download the abstract and the poster

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment

L.Fend, et al. ESMO 2024 Abstract available on the CICON website – Download the abstract and the poster

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

Article available on The Journal for ImmunoTherapy of Cancer (JITC)

Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers

A. Lalanne, et al. AACR 2024 Abstract available on the AACR website – Download the poster Poster Presentation

Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma

C. Ottensmeier, et al. ASCO 2023 Abstract available on the ASCO website – Download the abstract and the posterPoster Presentation

Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers

TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses

JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

V. Moreno et al. ESMO 2022 Download the poster here Poster Presentation

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors

Semmrich M, Marchand J, Fend L, et alJournal for ImmunoTherapy of Cancer Download the publication herePublication